Effect on carbohydrate metabolism and analysis of acceptability (menstrual cycle control) of extended regimens of the vaginally inserted hormone-releasing system 'NuvaRing' as compared with the standard 21/7 regime in reproductive-age women with type 1 diabetes mellitus

Gynecological Endocrinology

Volumn 26, Issue 9, 2010, Pages 663-668

  Grodnitskaya, Elena E ^a   Grigoryan, Olga R ^b   Klinyshkova, Elena V ^c   Andreeva, Elena N ^b   Melnichenko, Galina A ^b   Dedov, Ivan I ^b  

^a Centre of Family Planning and Reproduction   (Russian Federation)

^b N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^c Moscow Public Health Department   (Russian Federation)

Author keywords

contraception; Diabetes mellitus; hormone releasing system; reproductive age

Indexed keywords

ALBUMIN; ETHINYLESTRADIOL PLUS ETONOGESTREL; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ARTICLE; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; FEMALE; HEMOGLOBIN BLOOD LEVEL; HORMONE RELEASE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; PATIENT COMPLIANCE; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPOTTING; URINARY EXCRETION;

ADMINISTRATION, INTRAVAGINAL; ADULT; BLOOD GLUCOSE; CARBOHYDRATE METABOLISM; CONTRACEPTIVE AGENTS, FEMALE; DESOGESTREL; DIABETES MELLITUS, TYPE 1; DIABETIC RETINOPATHY; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ETHINYL ESTRADIOL; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INTRAUTERINE DEVICES, MEDICATED; MENSTRUAL CYCLE; PATIENT ACCEPTANCE OF HEALTH CARE;

EID: 77955804876     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513591003686296     Document Type: Article

References (11)

1. Jovanovic-Peterson L, Peterson CM. The art and science of maintenance of normoglycemia in pregnancies complicated by insulin-dependent diabetes mellitus. Endocr Pract 1996;2: 130-143.
2. Sacks DA. Preconception care for diabetic women: background, barriers, and strategies for effective implementation. Curr Diabetes Rev 2006;2:147-161.
3. Duijkers I, Killick S, Bigrigg A, Dieben TOM. A comparative study on the effects of contraceptive vaginal ring Nuva Ring and an oral contraceptive on carbohydrate metabolism and adrenal and thyroid function. Eur J Contracept Reprod Health Care 2004;9:131-140.
4. Elkind-Hirsch KE, Darensbourg C, Ogden B, Ogden LF, Hindelang P. Contraceptive vaginal ring use for women has less adverse metabolic effects than an oral contraceptive. Contraception 2007;76:348-356.
5. Klein BE, Moss SE, Klein R. Oral contraceptives in women with diabetes. Diabetes Care 1990;13:895-898.
6. Petersen KR, Skouby SO, Vedel P, Haaber AB. Hormonal contraception in women with IDDM. Influence on glycometabolic control and lipoprotein metabolism. Diabetes Care 1995;18:800-806.
7. Aubeny E, Buhler M, Colau JC, Vicaut E, Zadikian M, Childs M. Oral contraception: patterns of non-compliance. The compliance study. Eur J Contracept Reprod Health Care 2002;7:155-161.
8. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 2002;186:1142-1149.
9. Roumen FJ, Apter D, Mulders TM, Dieben TO. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 2001;16:469-475.
10. Miller L, Verhoeven C, Hout J. Extended regimens of the contraceptive vaginal ring. Obstet Gynecol 2005;106:473-482.
11. Barreiros FA, Guazzelli CA, de Araujo FF, Barbosa R. Bleeding patterns of women using extended regimens of the contraceptive vaginal ring. Contraception 2007;75:204-208.